Breast Cancer: Role of SPECT and PET in Imaging Bone Metastases

Seminars in Nuclear Medicine

Volumn 39, Issue 6, 2009, Pages 408-415

  Ben Haim, Simona ^a   Israel, Ora ^b,c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b Department of Nuclear Medicine ^*  (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18;

ADULT; BONE MARROW; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPHADENOPATHY; PARTIAL MASTECTOMY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70349432269     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2009.05.002     Document Type: Review

References (45)

1. Ries LAG, Melbert D, Krapacho M, et al (eds): SEER Cancer Statistics Review, 1975-2005. Bethesda, MD, National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2005/. Posted to the SEER web site 2008
2. American Cancer Society. Cancer Facts and Figures 2006 (2006), American Cancer Society, Atlanta, GA
3. Coleman R.E., and Rubens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer 55 (1987) 61-66
4. 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16 (1998) 3375-3379
5. Hamaoka T., Madewell J.E., Podoloff D.A., et al. Bone imaging in metastatic breast cancer. J Clin Oncol 22 (2005) 2924-2953
6. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic and hybrid modalities. J Nucl Med 46 (2005) 1356-1367
7. 99mTc-methylene diphosphonate. Semin Nucl Med 31 (2001) 28-49
8. Tryciecky E.W., Gottschalk A., and Ludema K. Oncologic imaging: Interactions of nuclear medicine with CT and MRI using the one scan as the model. Semin Nucl Med 27 (1997) 142-151
9. Shie P., Cardarelli R., Brandon D., et al. Meta-analysis: Comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 33 (2007) 97-101
10. Frank J.A., Ling A., Patronas N.J., et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. Am J Roentgenol 155 (1990) 1043-1048
11. Gosfield E., Alavi A., and Kneeland B. Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases. J Nucl Med 34 (1993) 2191-2198
12. Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am 45 (2007) 669-676
13. Coleman R.E., Rubens R.D., and Fogelman I. Reappraisal of the baseline bone scan in breast cancer. J Nucl Med 29 (1988) 1045-1049
14. Yeh K.A., Fortunato L., Ridge J.A., et al. Routine bone scanning in patients with T1 and T2 breast cancer: A waste of money. Ann Surg Oncol 2 (1995) 319-324
15. Maffioli L., Florimonte L., Pagani L., et al. Breast cancer: Diagnostic and therapeutic options. Eur J Nucl Med Mol Imaging 31 suppl 1 (2004) S143-S148
16. 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 36 (2006) 73-92
17. Coleman R.E., Mashiter G., Whitaker K.B., et al. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 29 (1988) 1354-1359
18. Vogel C.L., Schoenfelder J., Shemano I., et al. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 13 (1995) 1123-1128
19. Mortimer J.E., Dehdashti F., and Siegel B.A. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19 (2001) 2797-2803
20. Horger M., and Bares R. The role of single photon emission computed tomography/computed tomography in benign and malignant bone disease. Semin Nucl Med 36 (2006) 286-294
21. Yuh W.T.C., Zachar C.K., Barloon T.J., et al. Vertebral compression fractures: Distinction between benign and malignant causes with MR imaging. Radiology 172 (1989) 215-218
22. Even-Sapir E., Martin R.H., Barnes D.C., et al. Role of SPECT in differentiating malignant from benign lesions in the lower thoracic and lumbar vertebrae. Radiology 187 (1993) 193-198
23. Savelli G., Maffioli L., Maccauro M., et al. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med 45 (2001) 27-37
24. Gates G.F. SPECT bone scanning of the spine. Semin Nucl Med 28 (1998) 78-94
25. Kosuda S., Kaji T., Yokohama H., et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI?. J Nucl Med 37 (1996) 975-978
26. Han L.J., Au-Yong T.K., Tong W.C., et al. Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain. Eur J Nucl Med 25 (1998) 635-638
27. Uematsu T., Yuen S., Yukisawa S., et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. Am J Roentgenol 184 (2005) 1266-1272
28. Nakai T., Okuyama C., Kubota T., et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic skeletal metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 32 (2005) 1253-1258
29. Even-Sapir E., Flusser G., Lerman H., et al. SPECT/multislice low-dose CT: A clinically relevant constituent in the imaging algorithm of non oncologic patients referred for bone scintigraphy. J Nucl Med 48 (2007) 319-324
30. Utsunomiya D., Shiraishi S., Imuta M., et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: Comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology 238 (2006) 264-271
31. Cook G.J.R., and Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer Suppl 88 (2000) 2927-2933
32. Fogelman I., Cook G., Israel O., et al. Positron emission tomography and bone metastases. Semin Nucl Med 35 (2005) 135-142
33. 18F-fluoride PET/CT. J Nucl Med 45 (2004) 272-278
34. Schirmeister H., Guhlmann C.A., Elsner K., et al. Planar bone imaging vs. 18F-PET in patients with cancer of the prostate, thyroid and lung. J Nucl Med 40 (1999) 1623-1629
35. Schirmeister H., Guhlmann C.A., Kotzerke J., et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with 18F-fluoride ion and positron emission tomography. J Clin Oncol 17 (1999) 2381-2389
36. 18F] fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of skeletal metastases in breast cancer. J Clin Oncol 25 (2007) 3440-3447
37. Ohta M., Tokuda Y., Suzuki Y., et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: Comparison with 99mTc-MDP bone scintigraphy. Nucl Med Commun 22 (2001) 875-879
38. Yang S.N., Liang J.A., Lin F.J., et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 128 (2002) 325-328
39. Gallowitsch H.-J., Kresnik E., Gasser J., et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma. A comparison to conventional imaging. Invest Radiol 38 (2003) 250-256
40. Mahner S., Schirrmacher S., Brenner W., et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-d-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19 (2008) 1249-1254
41. Damle N., Bal C., Bandopadhyaya G., et al. Role of 18F fluoride PET/CT in the detection of bone metastases in breast cancer patients. (abstract). J Nucl Med 48 suppl 2 (2007) 142P
42. Stafford S.E., Gralow J.R., Schubert E.K., et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 9 (2002) 913-921
43. Eubank W.B., Mankoff D., Bhattacharya M., et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. Am J Roentgenol 183 (2004) 479-486
44. Tateishi U., Gamez C., Dawood S., et al. Bone metastases in patients with metastatic breast cancer: Morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 47 (2008) 189-196
45. Israel O., Goldberg A., Nachtigal A., et al. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging 33 (2006) 1280-1284